Sector Expert: Anthony Vendetti

Maxim Group

Image: Anthony Vendetti

Anthony Vendetti is the director of research and senior healthcare analyst at Maxim Group, LLC. Mr. Vendetti has been on Wall Street for more than 20 years and follows the medical device, healthcare information technology and services industries. Prior to joining Maxim Group, he was a senior healthcare analyst at Gruntal, UBS Securities and Ladenburg Thalmann. Mr. Vendetti also worked for three years in the healthcare industry at CIGNA, ultimately as a senior healthcare analyst in the managed care division.

Subscribe to
Streetwise Reports

Companies Commented On

Recent Interviews

Viveve's Treatment for Improving Women's Sexual Function May Leapfrog the Competition (10/5/16)
Viveve Medical 3-month chart

Private-pay aesthetic procedures constitute a trend in medical devices, according to Anthony Vendetti, Director of Research at Maxim Group. These nonreimbursable types of procedures have seen rapid growth in the past decade. In this interview with The Life Sciences Report, Vendetti discusses Viveve Medical, which is attempting to leapfrog the competition to get FDA approval to use its patented radiofrequency technology to improve women's sexual function.

Recent Quotes

"We believe VIVE's focus on attaining additional regulatory clearances, supporting its global distribution partners, expanding its direct sales force, and investing in market awareness, should position it for continued growth."

— Anthony Vendetti, Maxim Group (2/17/17)
more >

"We view VIVE's recent regulatory clearances as significant milestones (S. Korea, Brazil and the U.S.), as approval in these countries represents large market opportunities."

— Anthony Vendetti, Maxim Group (11/11/16)
more >

"Viveve has the technology, it's putting together a worldwide distribution network, and it has the management team to execute."

The Life Sciences Report Interview with Anthony Vendetti (10/5/16)
more >

"We would continue to be buyers of VIVE following its fourth consecutive quarter of double-digit revenue growth."

— Anthony Vendetti, Maxim Group (8/12/16)
more >

"VIVE is well-positioned to gain regulatory clearances in additional countries, which should lead to the Viveve System gaining further traction."

— Anthony Vendetti, Maxim Group (6/21/16)
more >

"The positive results of VIVE's VIVEVE I clinical trial builds upon the two previous clinical studies conducted in the U.S. and Japan."

— Anthony Vendetti, Maxim Group (4/27/16)
more >

"VIVE's MonaLisa Touch continues to be a critical driver of top-line growth."

— Anthony Vendetti, Maxim Group (3/9/16)
more >

"VIVE has a strong distribution platform that should incrementally drive system placements until expected FDA approval is attained in 1H18E."

— Anthony Vendetti, Maxim Group (1/27/16)
more >

Due to permission requirements, not all quotes are shown.